newsfilter
← Latest News
GlobeNewswire·

Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference

  • Design Therapeutics (NASDAQ: DSGN) announced management will join a fireside chat at the 2026 Cantor Fitzgerald Global Healthcare Conference on September 9, 2026, at 2:45 p.m. ET in New York.
  • A live webcast of the event will be accessible via the provided link & the investors section of designtx.com, with archives available for at least 30 days.
  • The company develops GeneTAC® gene-targeted chimera small molecules designed to modulate the expression of specific disease-causing genes.
  • Current clinical-stage programs include DT-216P2 for Friedreich ataxia, DT-168 for Fuchs endothelial corneal dystrophy, DT-818 for myotonic dystrophy type-1, & a program for Huntington's disease.
  • Discovery efforts are ongoing for multiple genomic medicines.